New York, NY -- (SBWIRE) -- 02/04/2013 -- Growing Stock Report initiates an Active OTC Stock Watch List and adds the following stocks: Advanced Cell Technology Inc. (OTC:ACTC) and Amarantus BioScience, Inc. (OTC:AMBS)
Advanced Cell Technology Inc. (OTC:ACTC) a biotechnology company that engages in the development and commercialization of human embryonic, induced pluripotency, and adult stem cell technology in the field of regenerative medicine is currently down (-2.46%) on over 3,870,940 shares traded. Last week, the Supreme Court of New York, New York County approved the issuance of the shares of (OTC:ACTC) Advanced Cell Technology, Inc.'s common stock that they agreed to issue to CAMOFI Master LDC and CAMHZN Master LDC pursuant to their Settlement Agreement and Mutual Release that they entered into on January 11, 2013. On January 23, 2013, they issued an aggregate of 80,357,143 shares to CAMOFI and CAMHZN as required by the Settlement Agreement and in reliance upon the exemption from registration under Section 3(a)(10) of the Securities Act of 1933. This news and activity in the stock has prompted Growing Stock Report to add Advanced Cell Technology Inc. (OTC:ACTC) to their Active OTC Stock Watch List.
Click Here to find out what other Investors are saying about Active OTC Stock Watch List.
Amarantus BioScience, Inc. (OTC:AMBS) a development-stage biotechnology company that focuses on the discovery and development of therapeutic proteins and biologics for the treatment of Parkinson?s disease, traumatic brain injury, and other human diseases in the United States is currently up (+3.57%) reported today that upon further analysis of the data reported on January 9th, 2013, the striatal reinnervation (densitometry) data produced in the 6 hydroxydopamine (6-OHDA) neurorestoration rat model of Parkinson's disease for MANF at 36ug achieved a statistically significant improvement over the data produced for GDNF, with a P value of 0.047.
"The statistical significance uncovered from our in-depth analysis underscores the challenges of evaluating dosing regimens for MANF in standard unilateral rodent models of Parkinson's disease due to MANF's unique ability to reinnervate the striatum," said Dr. John W. Commissiong, Chief Scientist at Amarantus. "We have been cautious in reporting this first of its kind data thus far, and intend to update the marketplace regarding certain aspects of our further analysis as we move forward. The Company is now preparing to initiate IND-enabling studies." The stock has reacted favorably so far, which has prompted Growing Stock Report to add Amarantus BioScience, Inc. (OTC:AMBS) to their Active OTC Stock Watch List.
Click Here to find out what other Investors are saying aboutAmarantus BioScience, Inc. (OTC:AMBS)
GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.
Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed.
Timing is important when trading Small Caps and Penny Stocks.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.GrowingStockReport.com
GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.
Growing Stock Report
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)